Empire Financial Management Company LLC Takes $210,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Empire Financial Management Company LLC acquired a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,000 shares of the company’s stock, valued at approximately $210,000.

Several other institutional investors and hedge funds have also modified their holdings of YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. boosted its position in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after buying an additional 3,416 shares during the period. Intech Investment Management LLC bought a new stake in Y-mAbs Therapeutics during the 3rd quarter worth approximately $133,000. SG Americas Securities LLC acquired a new position in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $178,000. Finally, Principal Financial Group Inc. bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at $267,000. 70.85% of the stock is currently owned by institutional investors.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the completion of the sale, the insider now owns 97,681 shares of the company’s stock, valued at $1,315,763.07. This represents a 39.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday. Finally, Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Stock Down 2.6 %

Shares of NASDAQ:YMAB opened at $10.01 on Thursday. The company has a 50 day moving average of $13.04 and a 200 day moving average of $12.71. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.09 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the company posted ($0.18) EPS. On average, research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.